Acquisitions and License Agreements (Schedule of Reconciliation of Total Consideration) (Details) - USD ($) $ in Millions	Aug. 31, 2016	Feb. 01, 2016	Sep. 25, 2015	Apr. 16, 2015	Aug. 14, 2014	Mar. 19, 2014	Oct. 01, 2012
Therakos
Business Acquisition [Line Items]
Total consideration, net of cash			$ 977.8
Plus: cash assumed in acquisition			41.3
Total consideration			1,019.1
Less: unpaid purchase consideration			0.0
Less: non-cash contingent consideration			0.0
Net assets acquired			$ 1,019.1
Ikaria
Business Acquisition [Line Items]
Total consideration, net of cash				$ 1,176.3
Plus: cash assumed in acquisition				77.3
Total consideration				1,253.6
Less: unpaid purchase consideration				0.0
Less: non-cash contingent consideration				0.0
Net assets acquired				$ 1,253.6
Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Total consideration, net of cash					$ 5,470.2
Plus: cash assumed in acquisition					445.1
Total consideration					5,915.3
Less: unpaid purchase consideration					(128.8)
Less: non-cash contingent consideration					0.0
Net assets acquired					$ 5,786.5
Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Total consideration, net of cash						$ 1,286.0
Plus: cash assumed in acquisition						43.2
Total consideration						1,329.2
Less: unpaid purchase consideration						0.0
Less: non-cash contingent consideration						0.0
Net assets acquired						$ 1,329.2
Stratatech [Member]
Business Acquisition [Line Items]
Total consideration, net of cash	$ 130.7
Plus: cash assumed in acquisition	0.2
Total consideration	130.9
Less: unpaid purchase consideration	0.0
Less: non-cash contingent consideration	(54.9)
Net assets acquired	$ 76.0
Hemostasis Products
Business Acquisition [Line Items]
Total consideration, net of cash		$ 222.2
Plus: cash assumed in acquisition		3.3
Total consideration		225.5
Less: unpaid purchase consideration		0.0
Less: non-cash contingent consideration		(52.0)
Net assets acquired		$ 173.5
CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Less: non-cash contingent consideration							$ (6.9)